IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs.
The mechanism(s) that regulates NK cell mobilization and the significance of this process to NK cell activity are unknown. After Con A-induced hepatitis, NK cells are mobilized from the spleen and bone marrow into the periphery in an IFN-gamma-dependent fashion. Intraperitoneal administration of IFN-gamma stimulates the mobilization of NK cells into the circulation, but not their cell death or proliferation. Increased number of circulating NK cells was coupled with their accumulation in the peritoneum, liver, and tumor-bearing lung tissue. Furthermore, increased number of NK cells in the lung reduced metastasis of Lewis lung carcinoma cells (3LL cell line) resulting in significantly extended NK-dependent survival. Mobilization of NK cells was specific and required the presence of T cells. Moreover, mobilization and migration of spleen NK cells in response to IFN-gamma treatment is dependent on the chemokine receptor CXCR3. Mechanistic insights regarding the role of IFN-gamma in the regulation of NK cell mobilization and their accumulation at sites of tumor metastasis may lead to the development of novel immunotherapy for cancer.
Goldyne Savad Institute of Gene Therapy, Hadassah University Hospital, Jerusalem, Israel.
Ori
O
Wald
Ido D
ID
Weiss
Hanna
H
Wald
Hadas
H
Shoham
Yochay
Y
Bar-Shavit
Katia
K
Beider
Eithan
E
Galun
Lola
L
Weiss
Liat
L
Flaishon
Idit
I
Shachar
Arnon
A
Nagler
Bao
B
Lu
Craig
C
Gerard
Ji-Liang
JL
Gao
Eyal
E
Mishani
Joshua
J
Farber
Amnon
A
Peled
D019264:Adoptive Transfer; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000276:immunology; D018827:Carcinoma, Lewis Lung / Q000276:immunology / Q000473:pathology / Q000628:therapy; D002450:Cell Communication / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury / Q000276:immunology / Q000473:pathology; D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; D019743:Chemokines, CXC / Q000378:metabolism; D003208:Concanavalin A / Q000633:toxicity; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000166:cytology / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology*
D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; D019743:Chemokines, CXC; C485433:Cxcl10 protein, mouse; C485969:Cxcl9 protein, mouse; C515188:Cxcr3 protein, mouse; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine; D011994:Recombinant Proteins; D003208:Concanavalin A; D007371:Interferon-gamma